Literature DB >> 7507857

c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture.

P J Simmons1, G W Aylett, S Niutta, L B To, C A Juttner, L K Ashman.   

Abstract

Using monoclonal antibody (MAB) YB5.B8, we have examined the expression of the c-kit protein, the receptor for the hematopoietic cytokine stem cell factor (SCF), on primitive hematopoietic cells. Bone marrow mononuclear cells (BMMNC) enriched for immature cells by differential agglutination using the lectin soybean agglutinin (SBA) were subjected to multiparameter fluorescence activated cell sorting (FACS) based on light-scattering properties, the expression of the c-kit protein and the CD34 antigen, and the retention of the vital fluorescent dye, Rhodamine 123 (Rh123). Sorted populations were assayed for their content of directly clonogenic progenitor cells (colony-forming units-granulocyte/macrophage [CFU-GM], burst-forming units-erythroid [BFU-E], and multipotential colony-forming units [CFU-Mix]) and for the presence of more primitive progenitor cells ("pre-CFU"). The latter were assayed by (1) their ability to initiate and sustain hematopoiesis in a standard stromal cell-dependent culture system and (2) their capacity for de novo generation of clonogenic progenitors in response to a combination of six recombinant hematopoietic cytokines in a stroma-independent suspension culture assay. A mean of 76% of CD34+ cells were found to coexpress c-kit. The majority of directly clonogenic cells (98% of CFU-GM, 98% of CFU-Mix, and 85% of BFU-E) were found in the CD34+c-kit+ fraction. Similarly, all pre-CFU were recovered in the CD34+c-kit+Rh123dull fraction, irrespective of whether the cells were maintained on marrow stromal cells or in cytokine-supplemented liquid culture. A mean of 87% (range 70-100%) of the CD34+Rh123dull cells also expressed c-kit. Since SCF has been reported to act as a growth factor for early lymphoid cells as well as myeloid cells, we looked for coexpression of c-kit and early lymphoid markers in the CD34+ population by multiparameter flow cytometry. Coexpression of c-kit on a minority of cells with markers of B or T lineages was observed. The majority of early lymphoid cells, however, appeared to lack c-kit expression. This was confirmed by the finding that only 4% of c-kit+CD34+ cells showed terminal deoxynucleotidyl transferase (TdT) activity, compared with 25% of the c-kit-CD34+ cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507857

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector.

Authors:  D M Shayakhmetov; T Papayannopoulou; G Stamatoyannopoulos; A Lieber
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  MiDReG: a method of mining developmentally regulated genes using Boolean implications.

Authors:  Debashis Sahoo; Jun Seita; Deepta Bhattacharya; Matthew A Inlay; Irving L Weissman; Sylvia K Plevritis; David L Dill
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

3.  Pasteurella multocida toxin-stimulated osteoclast differentiation is B cell dependent.

Authors:  Dagmar Hildebrand; Klaus Heeg; Katharina F Kubatzky
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

4.  Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.

Authors:  Lara Tickenbrock; Sina Hehn; Bülent Sargin; Georg Evers; Pavankumar Reddy Ng; Chunaram Choudhary; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve
Journal:  Int J Hematol       Date:  2008-07-31       Impact factor: 2.490

5.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Authors:  Robert Fritsche-Polanz; Marika Fritz; Andrea Huber; Karl Sotlar; Wolfgang R Sperr; Christine Mannhalter; Manuela Födinger; Peter Valent
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

6.  C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemia.

Authors:  Justin Loke; Paulynn Suyin Chin; Peter Keane; Anna Pickin; Salam A Assi; Anetta Ptasinska; Maria Rosaria Imperato; Peter N Cockerill; Constanze Bonifer
Journal:  Blood Adv       Date:  2018-02-13

7.  A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy.

Authors:  Cameron J Turtle; Hillary M Swanson; Nobuharu Fujii; Elihu H Estey; Stanley R Riddell
Journal:  Immunity       Date:  2009-10-29       Impact factor: 31.745

Review 8.  Cancer stem cells as targets for cancer therapy: selected cancers as examples.

Authors:  Sabine Hombach-Klonisch; Ted Paranjothy; Emilia Wiechec; Paola Pocar; Tarek Mustafa; Anja Seifert; Christian Zahl; Klaus Luis Gerlach; Katharina Biermann; Klaus Steger; Cuong Hoang-Vu; Klaus Schulze-Osthoff; Marek Los
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

9.  Inhibitory signaling sustains a distinct early memory CD8+ T cell precursor that is resistant to DNA damage.

Authors:  Jonathan B Johnnidis; Yuki Muroyama; Shin Foong Ngiow; Zeyu Chen; Sasikanth Manne; Zhangying Cai; Shufei Song; Jesse M Platt; Jason M Schenkel; Mohamed Abdel-Hakeem; Jean-Christophe Beltra; Allison R Greenplate; Mohammed-Alkhatim A Ali; Kito Nzingha; Josephine R Giles; Christelle Harly; John Attanasio; Kristen E Pauken; Bertram Bengsch; Michael A Paley; Vesselin T Tomov; Makoto Kurachi; Dario A A Vignali; Arlene H Sharpe; Steven L Reiner; Avinash Bhandoola; F Bradley Johnson; E John Wherry
Journal:  Sci Immunol       Date:  2021-01-15

10.  Mesenchymal stem cells promote a primitive phenotype CD34+c-kit+ in human cord blood-derived hematopoietic stem cells during ex vivo expansion.

Authors:  Viviana M Rodríguez-Pardo; Jean Paul Vernot
Journal:  Cell Mol Biol Lett       Date:  2012-10-27       Impact factor: 5.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.